Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
Moated ASX share crashes amid weak trading update
stocks
A collection of our best stock opportunities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,015.40 | 48.70 | 0.54% |
CAC 40 | 7,894.24 | 36.88 | 0.47% |
DAX 40 | 24,251.27 | 33.90 | 0.14% |
Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
FTSE 100 | 9,122.28 | 14.04 | -0.15% |
HKSE | 25,176.93 | 347.52 | -1.36% |
NASDAQ | 21,098.29 | 80.29 | -0.38% |
Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
S&P 500 | 6,370.86 | 0.00 | 0.00% |
S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
SSE Composite Index | 3,615.72 | 6.01 | 0.17% |